Ethyl 2-(6-bromo-2-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)acetate

Abstract

The title imidazo [4,5-b] pyridine derivative, C 16 H 14 BrN 3 O 2 , crystallizes with two independent molecules (1 and 2) in the asymmetric unit. In molecule 1, the pendant phenyl ring is inclined to the imidazo [4,5-b]pyridine core by 43.10 (4) while in molecule 2 the corresponding angle is 49.43 (4) . The two molecules differ primarily in the conformations of the ester substituents. In the crystal, molecules are linked via C-HÁ Á ÁN and C-HÁ Á ÁO hydrogen bonds, forming sheets parallel to the ab plane. Structure descriptionImidazo [4,5-b]pyridines are an important class of heterocyclic rings, considered as analogue of purine, widely studied owing to their broad biological activities. For example, they are known for their anticancer activity (Dash et al., 2008) and antibacterial (Capelli et al., 2006), antimitotic (Temple, 1990) and tuberculostatic (Bukowski & Janowiec, 1989) properties. In a previous study, we reported the synthesis of ethyl 2-(6-bromo-2-phenyl-1H-imidazo[4,5-b]-pyridin-1-yl)acetate (Hjouji et al., 2016). The present study is extended to the synthesis of the ethyl 2-(6-bromo-2-phenyl-3H-imidazo [4,5-b]pyridin-3-yl)acetate regioisomer, by the action of ethyl 2-bromoacetate on 6-bromo-2-phenyl-3H-imidazo [4,5-b]pyridine under the same conditions.The asymmetric unit of the title compound, contains two independent molecules (1 and 2), which differ primarily in the conformations of the ester substituents ( Figs. 1 and 2). The bicyclic imidazo [4,5-b]pyridine core of molecule 1 is planar to within 0.012 (1) Å , while that in molecule 2 is planar to within 0.020 (1) Å . In molecule 1, the pendant phenyl

Crystal structure, Hirshfeld surface analysis and DFT study of 6-bromo-3-(5-bromohexyl)-2-[4-(dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridine

“…7). For R = Ph and R" = Br, examples are UCOXES (R 0 = CH 2 COOC 2 H 5 ;Hjouji et al, 2016), UNUWIK [R 0 = (1-benzyl-1H-1,2,3-triazol-5-yl)methyl; Ouzidan et al, 2011a] and URAQOU [R 0 = (2-oxooxazolidin-3-yl)ethyl;Ouzidan et al, 2011b]…”